Europe Veterinary Vaccines Market worth $5.61 billion by 2031
The report "Europe Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), and End User (Hospitals, Clinics) – Forecast to 2031" is projected to grow from USD 4.08 billion in 2026 and to reach USD 5.61 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 6.6% during the forecast period.
Browse 250 market data Tables and 60 Figures spread through 300 Pages and in-depth TOC on "Europe Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), and End User (Hospitals, Clinics) – Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-veterinary-vaccines-market-72601323.html
Globally, the growing awareness regarding animal health, increasing pet population and pet ownership, initiatives by various governments to improve animal health, and growing adoption of pet insurance policies are propelling the adoption of veterinary vaccines in Europe. A large number of pet owners, especially those in Europe, are purchasing pet insurance because of the significant growth in pet care expenditure in recent years. Moreover, the increasing focus on new and advanced product development and the growing adoption of veterinary vaccines in emerging economies of Europe are expected to support the market growth during the forecast period. However, the high cost associated with vaccines is likely to hamper the development of the Europe veterinary vaccines market.
The companion animal vaccines segment is estimated to register the highest growth rate in the global Europe veterinary vaccines market in 2026.
By type, the companion animal vaccines market is estimated to grow at the highest rate in 2026. This growth is driven by increasing pet ownership, heightened awareness regarding preventive healthcare, and the development of more effective and safer vaccines. As pets are increasingly viewed as family members, the demand for vaccinations to protect them from infectious diseases is rising. The growing recognition of zoonotic disease risks, government regulations, and the rise of pet insurance are further boosting the demand for companion animal vaccines.
The veterinary hospitals segment is estimated to grow at a significant rate in the Europe veterinary vaccines market in 2026.
By end user, the veterinary hospitals segment is growing quickly as more pet owners seek professional care for their pets. With pets being treated like family, owners turn to veterinary hospitals for vaccinations and overall health care. These hospitals offer advanced vaccines and follow-up care, making them a go-to choice for ensuring pets stay healthy. Partnerships with pharmaceutical companies and the growing focus on preventive care are also helping drive this growth. As a result, veterinary hospitals are becoming an increasingly important part of the pet healthcare landscape.
“France is projected to register the highest growth during the forecast period.”
The France veterinary vaccines market is fast becoming one of the fastest-growing markets in Europe, owing to increased pet ownership, increased attention towards animal health, and increased awareness regarding zoonosis. Vaccines enhance productivity and food safety, owing to the strength of the livestock and poultry industries in the country. Additionally, advancements in vaccine technologies combined with government initiatives geared toward promoting preventive care are accelerating uptake in companion animals and livestock. France, therefore, stands as a major market for growth for veterinary vaccines in Europe.
The Europe veterinary vaccines market was dominated by Zoetis (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Europe Veterinary Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
